The FDA approved X4 Pharmaceuticals drug Xolremdi for treating WHIM syndrome. The molecule, which addresses the underlying cause of this rare immunodeficiency, was licensed from Sanofi’s Genzyme subsidiary.
Sanofi, which is leading development of the Denali Therapeutics-partnered molecule, disclosed little about the clinical trial results in ALS. But this Phase 2 failure follows the 2020 clinical trial pause of a different partnered molecule that addresses the same target.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Sanofi and Synthekine will work together to develop cytokine therapies for inflammatory diseases. This new alliance comes as Sanofi is salvaging a different cytokine therapy that showed disappointing efficacy in Phase 2 after the pharma giant acquired it in a $2.5 billion deal.
Insulin prices have long been a pain point for diabetics. The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development.
Sanofi is acquiring Inhibrx to get its hands on a drug candidate in pivotal testing for the protein deficiency alpha-1 antitrypsin deficiency, which leads to lung and liver problems. Inhibrx’s remaining assets will be spun out into a new company.
Sanofi, which markets the two primary treatments for Pompe disease, was trying to add a third one by licensing rights to a Maze Therapeutics drug candidate with a different therapeutic approach. A Federal Trade Commission complaint alleges the deal amounts to a monopoly player taking out its competition.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Formed by Baidu founder and CEO Robin Li, BioMap uses artificial intelligence technology to glean insight into proteins to guide biologic drug discovery. The startup is the latest company to join a growing list of Sanofi partners as the pharmaceutical giant continues investing in AI-enabled drug discovery.
Sanofi is interested in Recludix Pharma’s approach to treating inflammation with an oral small molecule that targets a protein thought to be undruggable. If it works, the drug could have safety and dosing advantages over currently available biologic drugs, including blockbuster Sanofi drug Dupixent.
AstraZeneca and Sanofi drug Beyfortus is now FDA approved for preventing respiratory problems from RSV infection in infants and toddlers. Antibody engineering enables the drug to last longer in the body, providing protective effects for potentially the entire RSV season.
An FDA advisory committee voted in favor of supporting a respiratory syncytial virus therapy designed to protect newborns and infants. The antibody drug developed by partners Sanofi and AstraZeneca is currently under regulatory review.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Frexalimab, a Sanofi drug candidate with roots at Dartmouth’s medical school, has met the main goal of its Phase 2 test. The encouraging data for this program come as different experimental Sanofi MS drug nears its one-year anniversary under FDA clinical hold.
The antibody drug, nirsevimab, is designed with a long half-life intended to protect infants from respiratory syncytial virus infection through the entire season. The drug, co-developed by AstraZeneca and Sanofi, is under FDA review.
Sanofi is acquiring rights to a Maze Therapeutics drug candidate for Pompe disease that could give the pharmaceutical giant another option to offer patients who have the rare metabolic disorder. In February, the drug posted positive data from a Phase 1 study.
Inato recently raised $20 million in Series A2 funding for its tech platform, which enables access to inclusive clinical trials. The two-way platform brings exposure to community-based providers who often are overlooked by Big Pharma for clinical trial sites by allowing providers to apply for clinical trials in which they're interested.
FDA approval of Sanofi hemophilia A drug Altuviiio provides patients with a therapeutic option that lasts longer than most other products available, including one already marketed by the French pharma giant. Altuviiio also gives Sanofi a way to better compete against blockbuster Roche drug Hemlibra.